( CAMBRIDGE Mass.--(BUSINESS WIRE)--May ...)Clinical Data on ARIAD's Novel mTOR Inhibitor, AP23573, To Be,Presented at the ASCO Annual Meeting,Health

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 25, 2007 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that clinical investigators from leading cancer centers will present Phase 2 and 1b clinical data from ongoing trials of the Company's novel mTOR inhibitor, AP23573, at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois, on Sunday, June 3, 2007. Additional data from the Phase 2 trial of single-agent AP23573 in patients with soft-tissue and bone sarcomas and initial results from the Phase 2 trial of single-agent AP23573 in progressive endometrial cancer will be presented. New data from the Phase 1b trial of AP23573 combined with the chemotherapy, paclitaxel, in patients with a broad range of solid tumors will be presented as well.

"As part of ARIAD's global clinical development plan and registration strategy, AP23573 is being studied in multiple clinical indications as a single agent and in combination with other therapies. We look forward to announcing results from several of these trials at ASCO," said Harvey J. Berger, M.D., Chairman and Chief Executive Officer of ARIAD. "This month marks an important milestone for our mTOR inhibitor as we recognize the fourth anniversary of ongoing treatment for the first patient dosed with AP23573 - a patient with metastatic carcinosarcoma. Her continued success remains an inspiration to all of us as we move to initiating our Phase 3 clinical trial in metastatic sarcomas during the third quarter of this year."

The schedule and meeting places for the sessions, together with the abstract numbers, are listed below: -0-

Sunday, June 3, 2007 at 2:45 p.m. to 3:00 p.m. - Oral Presentation

Session Title: mTOR Inhibitors: Ready for Prime Time?

Abstract No. 3509

"Phase 1b study defining the optimal dosing combinations of the mTOR

 inhibitor AP23573 and paclitaxel (PTX)"

Presenter: Diego Tosi, M.D.

Location: E Hall
'"/>




Page: 1 2 3 4 
Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin
Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S.,
From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe
Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy
of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule
Therapeutic Clinical Trial Results Presented at the 34th Annual
Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology
With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial
with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630
Clinical Data at ESMO Conference